RU2015151216A - Собетиром для лечения заболеваний, связанных с миелинизацией - Google Patents
Собетиром для лечения заболеваний, связанных с миелинизацией Download PDFInfo
- Publication number
- RU2015151216A RU2015151216A RU2015151216A RU2015151216A RU2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- sobetir
- condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| US61/819,467 | 2013-05-03 | ||
| USPCT/US2013/0053640 | 2013-08-05 | ||
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015151216A true RU2015151216A (ru) | 2017-06-08 |
| RU2015151216A3 RU2015151216A3 (enExample) | 2018-02-20 |
Family
ID=51843844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015151216A RU2015151216A (ru) | 2013-05-03 | 2014-02-05 | Собетиром для лечения заболеваний, связанных с миелинизацией |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (enExample) |
| EP (1) | EP2991670B8 (enExample) |
| JP (4) | JP2016517883A (enExample) |
| CN (1) | CN105431163A (enExample) |
| AU (1) | AU2014260468A1 (enExample) |
| BR (1) | BR112015027682A2 (enExample) |
| CA (1) | CA2911309A1 (enExample) |
| ES (1) | ES2745532T3 (enExample) |
| MX (2) | MX379043B (enExample) |
| RU (1) | RU2015151216A (enExample) |
| SG (2) | SG10201709090UA (enExample) |
| WO (2) | WO2014178892A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| EP3137116B1 (en) | 2014-04-30 | 2020-12-16 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| EP3180031A1 (en) | 2014-08-13 | 2017-06-21 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| CN108430514B (zh) * | 2015-10-29 | 2023-11-03 | 约翰霍普金斯大学 | 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法 |
| CN109641003A (zh) * | 2016-04-22 | 2019-04-16 | 维京治疗股份有限公司 | 甲状腺β-激动剂的应用 |
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| MX382313B (es) | 2016-05-18 | 2025-03-13 | Univ Oregon Health & Science | Derivados del sobetiroma. |
| US11325886B2 (en) | 2016-08-12 | 2022-05-10 | Oregon Health & Science University | Amide compounds, pharmaceutical compositions thereof, and methods of using the same |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| EP3615086A4 (en) | 2017-04-27 | 2021-01-06 | The Johns Hopkins University | COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| EP3644983B1 (en) | 2017-06-29 | 2023-10-25 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| US11633433B2 (en) | 2017-07-18 | 2023-04-25 | Keio University | Anti-bacterial composition against TH1 cell-inducing bacteria |
| WO2019094952A1 (en) | 2017-11-10 | 2019-05-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| EP3894383A1 (en) | 2018-12-12 | 2021-10-20 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| CN115279359A (zh) | 2019-11-29 | 2022-11-01 | 速通医疗公司 | 新型拟甲状腺素药 |
| WO2021113662A2 (en) | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| EP4168384A4 (en) | 2020-06-17 | 2024-07-10 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| EP4167986A4 (en) | 2020-06-17 | 2024-11-20 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| AU2022271304A1 (en) | 2021-05-06 | 2023-11-23 | Autobahn Therapeutics, Inc. | Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors |
| WO2023081458A1 (en) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systems and methods for diagnosis and/or treating demyelinating neuropathy |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| JP2000502086A (ja) | 1995-12-13 | 2000-02-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 核レセプターのリガンドおよびリガンド結合ドメイン |
| CA2260992C (en) | 1996-08-20 | 2004-03-09 | The Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| JP2002519340A (ja) | 1998-06-30 | 2002-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 甲状腺ホルモン類似体およびそれらの調製方法 |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| AU2004273986B2 (en) * | 2003-09-15 | 2010-04-22 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use in angiogenesis |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| CA2583410A1 (en) * | 2004-09-15 | 2006-03-23 | Albany College Of Pharmacy | Thyroid hormone analogs for promoting angiogenesis |
| US20090117054A1 (en) | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| NZ576424A (en) | 2006-10-20 | 2012-09-28 | Biogen Idec Inc | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| US8623861B2 (en) | 2006-11-03 | 2014-01-07 | Xin-Min Li | Method of treating demyelination diseases |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| EP2437730A4 (en) | 2009-05-20 | 2014-02-26 | Lingual Consegna Pty Ltd | ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2651357B1 (en) | 2010-12-16 | 2020-04-01 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| WO2014063720A1 (en) * | 2012-10-25 | 2014-05-01 | Renault Trucks | Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
-
2013
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en not_active Ceased
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
-
2014
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en not_active Ceased
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014178892A1 (en) | 2014-11-06 |
| MX379043B (es) | 2025-03-10 |
| JP6360552B6 (ja) | 2018-08-15 |
| JP6360552B2 (ja) | 2018-07-18 |
| SG10201709090UA (en) | 2017-12-28 |
| EP2991670B8 (en) | 2019-09-11 |
| EP2991670A1 (en) | 2016-03-09 |
| WO2014178931A8 (en) | 2015-11-26 |
| MX2021000538A (es) | 2021-04-28 |
| WO2014178892A8 (en) | 2015-12-17 |
| BR112015027682A2 (pt) | 2017-08-29 |
| SG11201509012QA (en) | 2015-11-27 |
| AU2014260468A1 (en) | 2015-11-19 |
| JP2016517883A (ja) | 2016-06-20 |
| CN105431163A (zh) | 2016-03-23 |
| US11510887B2 (en) | 2022-11-29 |
| US20160081955A1 (en) | 2016-03-24 |
| JP2018141024A (ja) | 2018-09-13 |
| US20200405669A1 (en) | 2020-12-31 |
| WO2014178931A1 (en) | 2014-11-06 |
| US10226438B2 (en) | 2019-03-12 |
| CA2911309A1 (en) | 2014-11-06 |
| MX2015015228A (es) | 2016-10-03 |
| JP2018162321A (ja) | 2018-10-18 |
| EP2991670A4 (en) | 2017-01-18 |
| HK1222552A1 (en) | 2017-07-07 |
| EP2991670B1 (en) | 2019-07-03 |
| ES2745532T3 (es) | 2020-03-02 |
| JP2016517884A (ja) | 2016-06-20 |
| US20190175531A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517884A5 (enExample) | ||
| Barnes et al. | Intravenous methylprednisolone for multiple sclerosis in relapse. | |
| FI3478712T3 (fi) | Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2016501865A5 (enExample) | ||
| CA2602950A1 (en) | Methods for the treatment of central nervous system injury via a tapered administration of progesterone | |
| JP2025510295A5 (enExample) | ||
| BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
| Oh et al. | Effect of ketamine and midazolam on oculocardiac reflex in pediatric strabismus surgery | |
| JP2016517421A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2020531527A5 (enExample) | ||
| Gordon | Sydenham’s chorea, and its complications affecting the nervous system | |
| JP2015508824A5 (enExample) | ||
| JP2022519007A5 (enExample) | ||
| Kondo et al. | Comparison of two low dose ACTH therapies for West syndrome: their efficacy and side effect | |
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| Li et al. | Telitacicept for minimal change disease | |
| US20110275807A1 (en) | Application of Evodiamine in preparing medicaments for Alzheimer's disease | |
| Jackson | Is minocycline useful for therapy of acute viral encephalitis? | |
| Smith | Anesthestic agents and status epilepticus | |
| JP2018500375A5 (enExample) | ||
| Tian et al. | Evaluation of N2O inhalation and oral midazolam conscious sedation in pediatric dentistry of children with intellectual disability | |
| Aradhey et al. | Foot Drop: A Rare Post COVID-19 Complication. | |
| Millichap | Reading epilepsy response to anticonvulsants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181126 |